A team at Kindai University in Osaka, Japan, fed ordinary L-arginine to fruit flies and mice engineered to develop ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

Amyloid-beta-targeted monoclonal antibodies had negligible effects for adults with mild cognitive impairment or AD-related dementia.

For more than 15 years, much of the Alzheimer’s Disease establishment has focused its attention—and hundreds of millions of research dollars—on the theory that the disease primarily is caused by the ...

About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the ...

Please provide your email address to receive an email when new articles are posted on . Decreased levels of plasma amyloid beta 42 at midlife, but not late life, correlated with an increased risk for ...

Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.